查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609174

下一代妇科癌症诊断市场：按组件、技术、适应症和最终用户划分 - 全球预测 2025-2030

Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

下一代妇科癌症诊断市场2023年估值为21.3亿美元，预计2024年将达到23.2亿美元，复合年增长率为10.49%，到2030年将达到42亿美元，预计将达到9000万美元。

下一代妇科癌症诊断市场包括在早期、可治疗阶段检测子宫颈癌、卵巢癌和子宫内膜癌等癌症的先进技术和方法。在癌症发生率上升、意识增强以及个人化医疗需求的推动下，这些诊断方法被证明比传统方法更准确和有效，最终改善患者的治疗效果极为重要。应用范围涵盖筛检、诊断和监测，主要最终用户包括医院、诊断实验室和研究机构。市场势头受到分子诊断技术进步、用于资料分析的人工智慧 (AI) 整合以及促进产品快速开发和核准的支援性监管环境的显着影响。扩大就地检验和加强液态切片技术存在机会，特别是在医疗基础设施有限的服务开拓地区。然而，该市场面临挑战，例如先进诊断工具的成本高昂、缺乏适当的报销政策以及阻碍开发中国家认识和获取的社会文化障碍。儘管存在这些障碍，创新和研究应专注于开发具有成本效益的解决方案，提高灵敏度和特异性，并推进可实现远距离诊断的远端医疗平台。利用次世代定序仪（NGS）、生物标记发现和人工智慧应用的平台对于市场进入者来说尤其有前景。与医疗保健提供者的策略联盟以及与学术机构的合作将加速创新，而对数位医疗的日益接受将进一步刺激市场扩张。调整卫生政策和增加研发投资可能会缓解现有的限制，但要抓住市场潜力，积极适应技术进步并解决全球医疗保健取得方面的差异至关重要。市场仍然充满活力，公司需要保持敏捷和前瞻性的方法，以开发下一代妇科诊断技术的巨大潜力。

主要市场统计
基准年[2023] 21.3亿美元
预计年份 [2024] 23.2亿美元
预测年份 [2030] 42.9亿美元
复合年增长率（%） 10.49%

市场动态：揭示快速发展的下一代妇科癌症诊断市场的关键市场洞察

供需的动态交互作用正在改变下一代妇科癌症诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 下一代妇科癌症患者增加
    • 倾向于疾病的早期诊断和治疗
    • 利用新的遗传标记
  • 市场限制因素
    • 下一代妇科癌症诊断相关的高成本
  • 市场机会
    • 远端医疗和远端监控新趋势
    • 增加筛检项目和医疗旅游
  • 市场问题
    • 製造下一代妇科癌症诊断测试​​的复杂性

波特五力：引领下一代妇科癌症诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解下一代妇科癌症诊断市场的外部影响

外部宏观环境因素在塑造下一代妇科癌症诊断市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解下一代妇科癌症诊断市场的竞争格局

下一代妇科癌症诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：下一代妇科癌症诊断市场供应商的绩效评估

FPNV 定位矩阵是评估下一代妇科癌症诊断市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製下一代妇科癌症诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对下一代妇科癌症诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 下一代妇科癌症发生率上升
      • 疾病的早​​期诊断和治疗趋势
      • 利用新的遗传标记
    • 抑制因素
      • 下一代妇科癌症诊断相关的高成本
    • 机会
      • 远端医疗和远端监控新趋势
      • 增加检测项目和医疗旅游
    • 任务
      • 製造下一代妇科癌症诊断测试​​的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章下一代妇科癌症诊断市场：按组成部分

  • 介绍
  • 消耗品
  • 装置
  • 软体

第七章下一代妇科癌症诊断市场：透过技术

  • 介绍
  • 次世代定序（NGS）
  • 聚合酵素链锁反应(PCR)

第八章下一代妇科癌症诊断市场：依适应症分类

  • 介绍
  • 子宫颈癌
  • 卵巢癌
  • 子宫癌

第九章下一代妇科癌症诊断市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 诊断实验室
  • 医院及门诊中心

第十章北美和南美下一代妇科癌症诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太下一代妇科癌症诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的下一代妇科癌症诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Fulgent Genetics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Interpace Diagnostics, LLC
  • Janssen Pharmaceuticals, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • Lucence Diagnostics Pte Ltd
  • Medtronic plc
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Novartis AG
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF1

The Next-Generation Gynecological Cancer Diagnostics Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 10.49%, to USD 4.29 billion by 2030.

The next-generation gynecological cancer diagnostics market encompasses advanced technologies and methods for detecting cancers such as cervical, ovarian, and endometrial at earlier and more treatable stages. With increased necessity driven by rising cancer prevalence, heightened awareness, and demand for personalized medicine, these diagnostics are pivotal in offering improved accuracy and efficiency over traditional methods, ultimately enhancing patient outcomes. Applications span screening, diagnostics, and monitoring, with major end-users including hospitals, diagnostic labs, and research institutions. The market's momentum is significantly influenced by technological advancements in molecular diagnostics, the integration of artificial intelligence (AI) for data analysis, and supportive regulatory landscapes, fostering expedited product development and approvals. Opportunities lie in expanding point-of-care testing and enhancing liquid biopsy techniques, particularly in underserved regions with limited access to healthcare infrastructure. However, the market faces challenges such as high costs of advanced diagnostic tools, a lack of adequate reimbursement policies, and socio-cultural barriers hindering awareness and accessibility in developing countries. Despite these obstacles, innovation and research should focus on cost-effective solution development, increasing sensitivity and specificity, and advancing telehealth platforms to enable remote diagnostics. Platforms leveraging next-gen sequencing (NGS), biomarker discovery, and AI applications are particularly promising for market entrants. Strategic partnerships with healthcare providers and academic collaborations can accelerate innovation, with the growing acceptance of digital health further stimulating market expansion. While healthcare policy adjustments and increased investment in R&D could mitigate existing limitations, capturing market potential requires proactive adaptation to technological advancements and addressing disparities in healthcare access globally. The market remains fundamentally dynamic, requiring businesses to remain agile and forward-thinking in their approach to tap into the vast potential of next-generation diagnostic technologies in gynecological healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.32 billion
Forecast Year [2030] USD 4.29 billion
CAGR (%) 10.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Gynecological Cancer Diagnostics Market

The Next-Generation Gynecological Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of next-generation gynecological cancer cases
    • Inclination towards early diagnosis and treatment of diseases
    • Utilization of novel markers and genetic markers
  • Market Restraints
    • High cost associated with next generation gynecological cancer diagnostics
  • Market Opportunities
    • Emerging trend of telemedicine and remote monitoring
    • Growing number of screening programs and medical tourism
  • Market Challenges
    • Complexity in manufacturing of next generation gynecological cancer diagnostics tests

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Gynecological Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Gynecological Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Gynecological Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Gynecological Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Gynecological Cancer Diagnostics Market

A detailed market share analysis in the Next-Generation Gynecological Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Gynecological Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Gynecological Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Gynecological Cancer Diagnostics Market

A strategic analysis of the Next-Generation Gynecological Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Gynecological Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Fulgent Genetics, Inc., GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Interpace Diagnostics, LLC, Janssen Pharmaceuticals, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Lucence Diagnostics Pte Ltd, Medtronic plc, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Novartis AG, QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Gynecological Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Components, market is studied across Consumables, Instruments, and Software.
  • Based on Technology, market is studied across Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR).
  • Based on Indication, market is studied across Cervical Cancer, Ovarian Cancer, and Uterine Cancer.
  • Based on End User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals & Ambulatory Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of next-generation gynecological cancer cases
      • 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
      • 5.1.1.3. Utilization of novel markers and genetic markers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with next generation gynecological cancer diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of telemedicine and remote monitoring
      • 5.1.3.2. Growing number of screening programs and medical tourism
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of next generation gynecological cancer diagnostics tests
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Next-Generation Gynecological Cancer Diagnostics Market, by Components

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Software

7. Next-Generation Gynecological Cancer Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing (NGS)
  • 7.3. Polymerase Chain Reaction (PCR)

8. Next-Generation Gynecological Cancer Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cervical Cancer
  • 8.3. Ovarian Cancer
  • 8.4. Uterine Cancer

9. Next-Generation Gynecological Cancer Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Ambulatory Centers

10. Americas Next-Generation Gynecological Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. ARUP Laboratories
  • 4. Becton, Dickinson and Company
  • 5. BGI Genomics Co., Ltd.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Centogene N.V.
  • 8. Danaher Corporation
  • 9. Epic Sciences Inc.
  • 10. Exact Sciences Corporation
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Fujifilm Holdings Corporation
  • 13. Fulgent Genetics, Inc.
  • 14. GE HealthCare Technologies, Inc.
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. Interpace Diagnostics, LLC
  • 18. Janssen Pharmaceuticals, Inc.
  • 19. Konica Minolta, Inc.
  • 20. Koninklijke Philips N.V.
  • 21. Lucence Diagnostics Pte Ltd
  • 22. Medtronic plc
  • 23. Merck KGaA
  • 24. Myriad Genetics, Inc.
  • 25. Natera, Inc.
  • 26. Novartis AG
  • 27. QIAGEN N.V.
  • 28. Siemens Healthineers AG
  • 29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023